The rationale for combining ipatasertib with an anti-PD-L1 agent is that AKT inhibitors may restore T-cell functions in the tumor microenvironment and promote the expansion of memory cells with a stem cell-like phenotype. The gene discussed is AKT1; the disease is neoplasm.